Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label trial of once-daily SIAC 30(B), SIAC 45(B), or insulin glargine plus metformin in type 2 diabetes
2007-002476-33Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing SIAC 30(B) plus metformin, SIAC 45(B) plus metformin and Insulin glargine plus metformin (3 arms). Primary endpoint: HbA1c after 16 weeks of treatment. Started Sep 2007; status: completed.
02
Drugs
SIAC 45(B)insulin glarginemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002476-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002476-33.